We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gene Network Sciences Announces Cancer Treatment Collaboration with Weill Cornell Medical College
News

Gene Network Sciences Announces Cancer Treatment Collaboration with Weill Cornell Medical College

Gene Network Sciences Announces Cancer Treatment Collaboration with Weill Cornell Medical College
News

Gene Network Sciences Announces Cancer Treatment Collaboration with Weill Cornell Medical College

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gene Network Sciences Announces Cancer Treatment Collaboration with Weill Cornell Medical College"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Gene Network Sciences (GNS) has announced that it has entered into a cancer treatment collaboration with the Weill Cornell Medical College (WCMC). Financial terms of the agreement were not disclosed.

Under the agreement, the parties will use GNS's proprietary REFS™ (reverse engineering and forward simulation) software platform to characterize the synergies between two commonly used classes of cancer drugs, farnesyl transferase inhibitors (FTIs) and taxanes.

"Phase I and II clinical trials have shown that the combination of FTIs and taxanes have clinical activity in taxane-refractory cancer patients," said Dr. Paraskevi Giannakakou, Weill Cornell's principal investigator for the collaboration and a leading authority on the mechanism of action of taxane-like drugs.

Dr. Giannakakou continued, "Discovering the molecular mechanism of action of this combination will pave the way towards identifying subsets of patients likely to benefit from this drug combination and will assist the rational development of therapeutic strategies able to overcome clinical drug resistance."

WCMC will use techniques to generate molecular-level data from the use of these drugs in model cancer systems. GNS will then build "in silico" models containing FTIs and taxanes together, allowing the parties to elucidate these drugs' synergistic mechanisms of efficacy and toxicity, biomarkers, and related biological insights.

"Our REFS™ technology provides the ability to simulate multiple drugs' activity in a disease system in a single model," said Colin Hill, CEO of GNS. "We aim through our collaborative research approach to develop better treatment options for cancer patients."

Advertisement